Dexcom Inc. will benefit from a new ahead-of-schedule ruling from the US Centers for Medicaid and Medicare Services providing coverage for continuous glucose monitors (CGM) defined as therapeutic by the agency. The firm says its G5 CGM is currently the only CGM on the market that meets CMS' requirement that the device can be used to make treatment decisions.
Dexcom First To CGM Reimbursement Finish Line
Following a recent approval for their G5 continuous glucose monitor for use in children and adults without a finger stick, Dexcom has scored big with a new US Centers for Medicaid and Medicare Services policy that would make their CGM the first of its kind eligible for reimbursement from the agency.